Cargando…

Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) represents chronic recurrent intestinal inflammation resulting from various factors. Crohn’s disease (CD) and ulcerative colitis (UC) have been identified as the two major types of IBD. Currently, most of the drugs for IBD used commonly in the clinic have adverse rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Linshan, Cheng, Shuyu, Li, Long, Liu, Yanling, Wang, Dan, Liu, Guoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316996/
https://www.ncbi.nlm.nih.gov/pubmed/34335253
http://dx.doi.org/10.3389/fphar.2021.684486
_version_ 1783729983491932160
author Duan, Linshan
Cheng, Shuyu
Li, Long
Liu, Yanling
Wang, Dan
Liu, Guoyan
author_facet Duan, Linshan
Cheng, Shuyu
Li, Long
Liu, Yanling
Wang, Dan
Liu, Guoyan
author_sort Duan, Linshan
collection PubMed
description Inflammatory bowel disease (IBD) represents chronic recurrent intestinal inflammation resulting from various factors. Crohn’s disease (CD) and ulcerative colitis (UC) have been identified as the two major types of IBD. Currently, most of the drugs for IBD used commonly in the clinic have adverse reactions, and only a few drugs present long-lasting treatment effects. Moreover, issues of drug resistance and disease recurrence are frequent and difficult to resolve. Together, these issues cause difficulties in treating patients with IBD. Therefore, the development of novel therapeutic agents for the prevention and treatment of IBD is of significance. In this context, research on natural compounds exhibiting anti-inflammatory activity could be a novel approach to developing effective therapeutic strategies for IBD. Phytochemicals such as astragalus polysaccharide (APS), quercetin, limonin, ginsenoside Rd, luteolin, kaempferol, and icariin are reported to be effective in IBD treatment. In brief, natural compounds with anti-inflammatory activities are considered important candidate drugs for IBD treatment. The present review discusses the potential of certain natural compounds and their synthetic derivatives in the prevention and treatment of IBD.
format Online
Article
Text
id pubmed-8316996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83169962021-07-29 Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease Duan, Linshan Cheng, Shuyu Li, Long Liu, Yanling Wang, Dan Liu, Guoyan Front Pharmacol Pharmacology Inflammatory bowel disease (IBD) represents chronic recurrent intestinal inflammation resulting from various factors. Crohn’s disease (CD) and ulcerative colitis (UC) have been identified as the two major types of IBD. Currently, most of the drugs for IBD used commonly in the clinic have adverse reactions, and only a few drugs present long-lasting treatment effects. Moreover, issues of drug resistance and disease recurrence are frequent and difficult to resolve. Together, these issues cause difficulties in treating patients with IBD. Therefore, the development of novel therapeutic agents for the prevention and treatment of IBD is of significance. In this context, research on natural compounds exhibiting anti-inflammatory activity could be a novel approach to developing effective therapeutic strategies for IBD. Phytochemicals such as astragalus polysaccharide (APS), quercetin, limonin, ginsenoside Rd, luteolin, kaempferol, and icariin are reported to be effective in IBD treatment. In brief, natural compounds with anti-inflammatory activities are considered important candidate drugs for IBD treatment. The present review discusses the potential of certain natural compounds and their synthetic derivatives in the prevention and treatment of IBD. Frontiers Media S.A. 2021-07-14 /pmc/articles/PMC8316996/ /pubmed/34335253 http://dx.doi.org/10.3389/fphar.2021.684486 Text en Copyright © 2021 Duan, Cheng, Li, Liu, Wang and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Duan, Linshan
Cheng, Shuyu
Li, Long
Liu, Yanling
Wang, Dan
Liu, Guoyan
Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
title Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
title_full Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
title_fullStr Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
title_full_unstemmed Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
title_short Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
title_sort natural anti-inflammatory compounds as drug candidates for inflammatory bowel disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316996/
https://www.ncbi.nlm.nih.gov/pubmed/34335253
http://dx.doi.org/10.3389/fphar.2021.684486
work_keys_str_mv AT duanlinshan naturalantiinflammatorycompoundsasdrugcandidatesforinflammatoryboweldisease
AT chengshuyu naturalantiinflammatorycompoundsasdrugcandidatesforinflammatoryboweldisease
AT lilong naturalantiinflammatorycompoundsasdrugcandidatesforinflammatoryboweldisease
AT liuyanling naturalantiinflammatorycompoundsasdrugcandidatesforinflammatoryboweldisease
AT wangdan naturalantiinflammatorycompoundsasdrugcandidatesforinflammatoryboweldisease
AT liuguoyan naturalantiinflammatorycompoundsasdrugcandidatesforinflammatoryboweldisease